MedTrace Logo

High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma

NCT00287924 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well high-dose methotrexate works in treating young patients with residual ependymoma.

Conditions

Interventions

DRUG

methotrexate

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Martin W. English, MD · Birmingham Children's Hospital

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2010-03-31

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287924 on ClinicalTrials.gov